- Home
- MPV vs PBYI Comparison
MPV vs PBYI Comparison
Compare MPV & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPV
- PBYI
- Stock Information
- Founded
- MPV 1988
- PBYI 2010
- Country
- MPV United States
- PBYI United States
- Employees
- MPV N/A
- PBYI N/A
- Industry
- MPV Finance Companies
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- MPV Finance
- PBYI Health Care
- Exchange
- MPV Nasdaq
- PBYI Nasdaq
- Market Cap
- MPV 170.6M
- PBYI 176.1M
- IPO Year
- MPV N/A
- PBYI N/A
- Fundamental
- Price
- MPV $16.09
- PBYI $2.32
- Analyst Decision
- MPV
- PBYI Strong Buy
- Analyst Count
- MPV 0
- PBYI 1
- Target Price
- MPV N/A
- PBYI $7.00
- AVG Volume (30 Days)
- MPV 25.2K
- PBYI 393.6K
- Earning Date
- MPV 01-01-0001
- PBYI 10-31-2024
- Dividend Yield
- MPV 8.71%
- PBYI N/A
- EPS Growth
- MPV N/A
- PBYI N/A
- EPS
- MPV 1.71
- PBYI 0.18
- Revenue
- MPV N/A
- PBYI $219,143,000.00
- Revenue This Year
- MPV N/A
- PBYI N/A
- Revenue Next Year
- MPV N/A
- PBYI N/A
- P/E Ratio
- MPV $9.35
- PBYI $12.75
- Revenue Growth
- MPV N/A
- PBYI N/A
- 52 Week Low
- MPV $11.18
- PBYI $2.13
- 52 Week High
- MPV $16.42
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- MPV 52.88
- PBYI 34.73
- Support Level
- MPV $15.88
- PBYI $2.23
- Resistance Level
- MPV $16.39
- PBYI $2.56
- Average True Range (ATR)
- MPV 0.29
- PBYI 0.17
- MACD
- MPV 0.04
- PBYI -0.01
- Stochastic Oscillator
- MPV 52.84
- PBYI 14.06
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.